Efficacy and Safety of Abatacept Combined With JAK Inhibitor for Refractory Rheumatoid Arthritis

Zhejiang Provincial People's Hospital90 enrolled

Overview

The aim of this study is to observe the clinical efficacy and safety of abatacept combined with JAK inhibitor in the treatment of D2TRA patients

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Abatacept Treatment Compliance Rheumatoid Arthritis

Interventions

Janus Kinase InhibitorDRUG

One group of D2TRA subjects receive Janus Kinase Inhibitors combine Abatacept treatment, another group of D2TRA subjects receive Abatacept treatment only.

AbataceptDRUG

One group of D2TRA subjects receive Janus Kinase Inhibitors combine Abatacept treatment, another group of D2TRA subjects receive Abatacept treatment only.

Eligibility

Sex: ALLHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: 1. Meet the above diagnostic criteria for refractory rheumatoid arthritis 2. The traditional disease-improving rheumatic drug treatment is ineffective, and the use of two or more biological/targeted disease-improving anti-rheumatic drugs is ineffective, and abatacept combined with a JAK inhibitor is required treated patients Exclusion Criteria: 1. Patients with tumors, hematological diseases, and other autoimmune diseases 2. Those who have a history of allergies to the drugs selected in this study 3. Those who cannot adhere to abatacept combined with JAK inhibitor therapy, or who have serious adverse reactions and did not complete the observation period prescribed by the study

Locations (1)

Zhejiang Provincial People's Hospital

Hangzhou, Zhejiang, China

RECRUITING

Outcomes

Primary Outcomes

Efficacy of Abatacept Combined With JAK Inhibitor for Refractory Rheumatoid Arthritis

The disease activity score of 28 joints with erythrocyte sedimentation rate (DAS28-ESR ≤ 2.6, remission; 2.6 \< DAS28-ESR ≤ 3.2, mild activity; 3.2 \< DAS28-ESR ≤ 5.1, moderate activity, and DAS28-ESR \> 5.1, severe activity)

Time frame: maximum 1 years

Secondary Outcomes

Incidence of Treatment-Emergent Adverse EventsArthritis

Liver and kidney function

Time frame: maximum 1 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.